Cytodyn inc   (CYDY)
Other Ticker:  
Price: $0.1671 $0.00 1.211%
Day's High: $0.1748 Week Perf: 0.97 %
Day's Low: $ 0.16 30 Day Perf: 1.33 %
Volume (M): 2,455 52 Wk High: $ 0.48
Volume (M$): $ 410 52 Wk Avg: $0.23
Open: $0.17 52 Wk Low: $0.15

 Market Capitalization (Millions $) 160
 Shares Outstanding (Millions) 959
 Employees 25
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -53
 Cash Flow (TTM) (Millions $) 2
 Capital Exp. (TTM) (Millions $) 0

Cytodyn Inc
CytoDyn Inc. is a biotechnology company that focuses on the development of innovative therapies for the treatment of cancer and immune disorders. The company is headquartered in Vancouver, Washington, and was founded in 200

CytoDyn's lead product, leronlimab (PRO 140), is a monoclonal antibody that targets the CCR5 receptor, which is a protein found on the surface of certain immune cells. CCR5 is involved in the regulation of the immune system, and blocking the receptor has been shown to be effective in treating a variety of diseases, including HIV, cancers, and autoimmune disorders.

Leronlimab has been granted fast-track designation by the U.S. Food and Drug Administration (FDA) for HIV and metastatic triple-negative breast cancer, and has also received orphan drug designation for glioblastoma, a type of brain cancer. The drug is currently in clinical trials for a range of indications, including breast cancer, COVID-19, and NASH (non-alcoholic steatohepatitis).

CytoDyn also has a pipeline of other CCR5-targeting drugs in various stages of development, including Cytolin, a combination therapy for HIV, and CCR5-Delta 32 Stem Cell Therapy, a potentially curative gene therapy for HIV.

In addition to its clinical development programs, CytoDyn also has collaborations with other pharmaceutical companies, research institutions, and government agencies to develop new therapies for a variety of diseases.

Overall, CytoDyn is a promising biotech company that is focused on developing innovative therapies for the treatment of challenging diseases. Its lead product, leronlimab, has shown significant promise in clinical trials, and the company is well-positioned to continue advancing its pipeline of CCR5-targeting drugs.

   Company Address: 1111 Main Street Vancouver 98660 WA
   Company Phone Number: 980-8524   Stock Exchange / Ticker: CYDY
   CYDY is expected to report next financial results on April 09, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Cytodyn Inc

Cytodyn Inc Surpasses Expectations with Impressive Q2 2024 Financial Results, Signaling Promising Growth for Shareholders

Cytodyn Inc Reports Significant Improvement in Earnings for Q2 2024
In the Major Pharmaceutical Preparations sector, the focus is often on the large companies, but it is important not to overlook the lesser-known corporations that are making strides in the industry. Cytodyn Inc, a relatively unknown company, recently announced its earnings for the second quarter of 2024 and the results are encouraging.
Cytodyn Inc reported an operating deficit of $-3.398 million for the second quarter of 2024. This is a significant improvement compared to the operating deficit of $-23.163 million in the same quarter of the previous year. Such positive financial performance is a strong indicator of the company's overall condition and its ability to navigate the challenging pharmaceutical landscape.

Cytodyn Inc

The Major Pharmaceutical Preparations Company Surprises Shareholders with Striking Fiscal Improvement: Operating Deficit Decreases to $-4.612 Million

The Major Pharmaceutical Preparations industry has been facing multiple challenges, and Cytodyn Inc is no exception. The recently disclosed operating deficit of $-4.612 million for the fiscal first quarter of 2024 is a clear indication of the struggles the company is currently facing. This result reflects a significant decline in productivity compared to the previous fiscal year ending August 31, 2022.
While there was some slight improvement in reducing the losses from the same quarter a year ago, it is not enough to instill confidence in investors. The deficit was $-11.571 million in the first quarter of 2023, highlighting an ongoing issue for Cytodyn Inc. The company must work hard to address these losses and find a way to mitigate the financial challenges it faces.

Cytodyn Inc

Cytodyn Inc. Makes Strides Toward Cost-Effectiveness, Reports Operating Shortfall Reduction in Fourth Quarter of 2023

Cytodyn Inc., a prominent player in the Major Pharmaceutical Preparations industry, has recently been under scrutiny by industry veterans regarding its performance in the fourth quarter of 2023. The company reported an operating shortfall of $-3.78 million for the period from March to May 2023, without stating any revenue.
One significant aspect that caught the attention of industry observers is the company's ability to operate more cost-effectively compared to the previous year. In the corresponding period of the preceding year, Cytodyn Inc. had an operating shortfall of $-79.048 million. The commendable progress made in reducing these losses could be a positive sign for the company's future prospects, positioning it as a potential bellwether in the industry.

Cytodyn Inc

Cytodyn Inc disclosed operating shortfall in the third quarter of 2023

As the earnings season for the period of December to February 28, 2023 progresses, many companies have disclosed their respective financial numbers. Among them are several businesses operating in the Major Pharmaceutical Preparations sector. One such company that has recently revealed its financials is CYDY, which disclosed an operating shortfall of $-3.921 million for the financial period ending February 28, 2023.
It is evident that CYDY?s current performance has overshadowed its performance in the same period of the previous year. This is an indication that the management has been working mainly in the expansion phase, which is one of the significant takeaways from this scenario. During the financial period closing February 28, 2023, the company?s management has made the operations of Cytodyn Inc. more cost-effective and has reduced the deficit to $-13.702 million.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com